Deadline: 21-Apr-2026
Pfizer is funding independent medical education projects to improve healthcare professional knowledge and competence in HER2-positive metastatic breast cancer, particularly focusing on first-line maintenance therapy, evolving treatment paradigms, and therapy safety profiles. Eligible organisations can receive $10,000 to $250,000 for educational initiatives that strengthen clinical decision-making and patient care in this therapeutic area.
Overview of the Funding Opportunity
Pfizer’s initiative supports independent medical education projects aimed at enhancing healthcare professionals’ understanding of HER2-positive metastatic breast cancer, with emphasis on first-line maintenance therapy and evolving treatment standards. The programme encourages educational activities that improve treatment optimization and informed decision-making for patients.
Priority Focus Areas
-
First-line HER2+ metastatic breast cancer maintenance therapies and combination strategies
-
Evolving first-line standard-of-care options for HER2-positive metastatic breast cancer patients
-
Safety profiles of available therapies and their clinical implications
Objectives of the Initiative
The funding opportunity aims to:
-
Enhance clinical knowledge of healthcare providers regarding HER2-positive metastatic breast cancer
-
Update professionals on emerging evidence and treatment strategies from recent clinical trials
-
Support evidence-based decision-making for optimized patient care
Eligible Activities
Projects may include:
-
Educational workshops, seminars, or online courses for healthcare professionals
-
Development of educational materials or modules covering first-line maintenance and treatment strategies
-
Activities addressing safety, therapy combinations, and evolving clinical standards
-
Programs that qualify for continuing education credits, provided appropriate accreditation
Funding and Duration
-
Funding range: $10,000 to $250,000 per project
-
Preferred duration: approximately 18 months, though shorter or longer projects may be considered
-
Funding covers costs directly related to educational project delivery and implementation
Who is Eligible
Eligible organisations include:
-
Medical, dental, nursing, allied health, and pharmacy professional schools
-
Healthcare institutions of any size
-
Professional organisations and medical societies
-
Medical education companies or entities advancing healthcare professional education
Eligibility Requirements
-
Individual applicants and independent physician practice groups not affiliated with recognized institutions are ineligible
-
Project lead must be an employee or contractor of the applying organisation
-
Requesting organisation must be legally able to receive funding directly from Pfizer
-
For collaborative projects across multiple institutions, each entity must have a clearly defined role
-
Organisations providing continuing education must hold appropriate accreditation
Why It Matters
This funding supports education in a rapidly evolving treatment landscape, ensuring healthcare professionals remain informed about new therapies, evidence-based practices, and patient management strategies in HER2-positive metastatic breast cancer. It contributes to improved clinical decision-making, patient outcomes, and the overall quality of care.
Common Tips and Mistakes to Avoid
Tips for Applicants: Focus on projects that clearly address first-line maintenance therapy and evolving treatment paradigms, demonstrate measurable impact, and meet accreditation standards for continuing education if applicable. Common Mistakes: Requesting funding for non-educational activities, applying as an individual without institutional affiliation, or failing to define roles in multi-institution collaborations.
Frequently Asked Questions (FAQs)
1. Who can apply? Organisations involved in healthcare professional education or improvement, including medical schools, healthcare institutions, professional organisations, and medical education companies.
2. What funding amount is available? $10,000 to $250,000 per project.
3. What is the preferred project duration? Approximately 18 months, with flexibility for shorter or longer timelines.
4. Can individual healthcare professionals apply? No, applicants must be affiliated with recognised institutions.
5. Are collaborative projects allowed? Yes, but each participating organisation must have a clearly defined role.
6. Can projects provide continuing education credits? Yes, if the requesting organisation holds appropriate accreditation.
7. What topics should the educational activities cover? First-line maintenance therapies, evolving standard-of-care options, therapy combinations, and safety profiles.
Conclusion
Pfizer’s funding opportunity advances healthcare professional education in HER2-positive metastatic breast cancer, strengthening knowledge of first-line maintenance strategies and evolving therapies. Funded projects will support evidence-based patient care, improve clinical competence, and enhance treatment outcomes in this therapeutic area.
For more information, visit Pfizer.
